As companies face pressure to ensure access to medicines during the pandemic, Novartis (NVS) plans to sell more than a dozen older drugs at cost to nearly 80 mostly poor countries, a move that was met with mixed reaction from consumer advocates because pricing was not disclosed.

The drug maker is creating a nonprofit to sell 15 generic and over-the-counter medicines that treat various symptoms of Covid-19 to low-income and lower-middle-income countries. Among the medicine are several antibiotics as well as dexamethasone, a steroid that recent top-line study data suggests the steroid may improve the odds of survival in the sickest Covid-19 patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I can’t unlock the articles I want to read unless I buy a subscription to Stat plus and I’ve been able to log onto your site and access your articles from the beginning of March. What has changed? Do I now have to subscribe even though I have an account???? Pam Harrison

  • Per Matt Herper’s statement from another Stat article just published:

    Hydroxychloroquine did not lead to faster symptom improvement among patients who had Covid-19 symptoms but were not hospitalized, according to a new study.

    How does this initiative jive?

    The drug maker (Novartis) is creating a nonprofit to sell 15 generic and over-the-counter medicines that treat various symptoms of Covid-19 to low-income and lower-middle-income countries.

    Would this nonprofit prohibited to sell hyrroxychloroquine? I highly doubt it, especially with Trump not stopping to hype about taking it himself. We all know how many obstinate and uninformed people we have in the US who believe everything our USPTO says in public.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy